Aileron Therapeutics, Inc.ALRNNASDAQ
LOADING
|||
Year-over-year research & development expense growth
| Period | Value |
|---|---|
| Q3 2025 | -60.83% |
| Q2 2025 | 40.54% |
| Q1 2025 | -8.07% |
| Q4 2024 | -10.75% |
| Q3 2024 | -0.51% |
| Q2 2024 | 8.03% |
| Q1 2024 | 75.61% |
| Q4 2023 | 8863.64% |
| Q3 2023 | -88.24% |
| Q2 2023 | -89.67% |
| Q1 2023 | -24.65% |
| Q4 2022 | -43.34% |
| Q3 2022 | -21.98% |
| Q2 2022 | -7.81% |
| Q1 2022 | 29.20% |
| Q4 2021 | 6.62% |
| Q3 2021 | 11.03% |
| Q2 2021 | -10.73% |
| Q1 2021 | 124.21% |
| Q4 2020 | -28.28% |
| Q3 2020 | 7.88% |
| Q2 2020 | -38.85% |
| Q1 2020 | -13.61% |
| Q4 2019 | 5.25% |
| Q3 2019 | 3.97% |
| Q2 2019 | 3.11% |
| Q1 2019 | 5.38% |
| Q4 2018 | -8.33% |
| Q3 2018 | -18.78% |
| Q2 2018 | 9.78% |
| Q1 2018 | 12.41% |
| Q4 2017 | 12.71% |
| Q3 2017 | 21.01% |
| Q2 2017 | 7.44% |
| Q1 2017 | -4.85% |
| Q4 2016 | 18.69% |
| Q3 2016 | 24.88% |
| Q2 2016 | -16.33% |
| Q1 2016 | 23.35% |
| Q4 2015 | 13.80% |